# EDGAR Filing Document

**Accession Number:** 0001727196
**File Stem:** 0001104659-25-111931
**Filing Date:** 2025-11
**Character Count:** 25683
**Document Hash:** 12a837561c0c7fac0355ac317062ae9e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-111931.hdr.sgml**: 20251114

**ACCESSION NUMBER**: 0001104659-25-111931

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 29

**CONFORMED PERIOD OF REPORT**: 20251114

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20251114

**DATE AS OF CHANGE**: 20251114

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Scholar Rock Holding Corp
- **CENTRAL INDEX KEY:** 0001727196
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 823750435
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38501
- **FILM NUMBER:** 251481135

**BUSINESS ADDRESS:**
- **STREET 1:** 301 BINNEY STREET
- **STREET 2:** 3RD FLOOR
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02142
- **BUSINESS PHONE:** 857-259-3860

**MAIL ADDRESS:**
- **STREET 1:** 301 BINNEY STREET
- **STREET 2:** 3RD FLOOR
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02142

?xml version='1.0' encoding='ASCII'? Scholar Rock Holding Corporation_November 14, 2025

------

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

------

**FORM 8-K**

------

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event Reported): November 14, 2025

**Scholar Rock Holding Corporation**

(Exact Name of Registrant as Specified in Charter)

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Delaware** |  | **001-38501** |  | **82-3750435** |
| (State or Other Jurisdiction of<br>Incorporation) |  | (Commission File Number) |  | (I.R.S. Employer Identification Number) |

---

**301 Binney Street, 3rd Floor, Cambridge, MA 02142**

(Address of Principal Executive Offices) (Zip Code)

**(857) 259-3860**

(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| &nbsp;&nbsp;Common Stock, par value $0.001 per share | &nbsp;&nbsp;SRRK | &nbsp;&nbsp;The Nasdaq Global Select Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 2.02. Results of Operations and Financial Condition.**

On November 14, 2025, Scholar Rock Holding Corporation (the "Company") issued a press release announcing its financial and operating results for the fiscal quarter ended September 30, 2025. A copy of the press release is being furnished as Exhibit 99.1 to this Report on Form 8-K.

The information in this Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as expressly set forth by specific reference in such filing.

**Item 7.01. Regulation FD Disclosure.**

The Company will utilize slides during its conference call scheduled for 8:00 am ET on November 14, 2025 to announce its financial and operating results for the fiscal quarter ended September 30, 2025 and to provide a business update on the Company. A copy of the slides is furnished as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated by reference into this Item 7.01 as if fully set forth herein.

The information in this Current Report on Form 8-K and Exhibits 99.1 and 99.2 attached hereto are intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such filing.

#### Item 9.01. Financial Statements and Exhibits.
(d) Exhibits

---

| | |
|:---|:---|
| **ExhibitNo.** | **Description** |
| 99.1 | [Press Release issued by the Company on November 14, 2025, furnished hereto.](srrk-20251114xex99d1.htm) |
| 99.2 | [Presentation Slides for November 14, 2025 Conference Call, furnished hereto.](srrk-20251114xex99d2.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

#### SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **Scholar Rock Holding Corporation** | **Scholar Rock Holding Corporation** |
| Date: November 14, 2025 | By: | /s/ Junlin Ho |
|  |  | Junlin Ho |
|  |  | General Counsel & Corporate Secretary |

---

## Exhibit 99.1

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](srrk-20251114xex99d1g001.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Exhibit 99.1 Scholar Rock Reports Third Quarter 2025 Financial Results and Recent Business Highlights • Completed constructive and collaborative in-person Type A meeting with U.S. Food and Drug Administration (FDA) on November 12th for apitegromab biologics license application (BLA) for the treatment of children and adults with spinal muscular atrophy (SMA) • Catalent Indiana, LLC (part of Novo Nordisk) participated in the Type A meeting in person and presented the progress made in implementing the remediation plan; confirmed to FDA that the site is on-track to be reinspection ready by the end of this year • Resubmission of BLA and U.S. launch following approval of apitegromab for children and adults with SMA anticipated in 2026 • Timelines accelerated with additional apitegromab U.S. fill-finish facility; tech transfer underway with commercial capacity reserved beginning in Q1 2026 • Dosing underway in Phase 2 OPAL study evaluating apitegromab in infants and toddlers <2 years of age with SMA • FDA cleared SRK-439 Investigational New Drug (IND) application; dosing in healthy volunteers to commence in Q4 2025 • Cash, cash equivalents and marketable securities of $369.6 million as of September 30, 2025; expected to fund operations into 2027 • Company to host conference call today at 8:00 a.m. ET CAMBRIDGE, Mass.--(BUSINESS WIRE)— November 14, 2025 — Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to dramatically improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology to advance musculoskeletal health, today reported financial results for the third quarter ended September 30, 2025, and provided an update on recent company developments. "We are unwavering in our commitment to bring apitegromab, the world's first and only muscle-targeted treatment to improve motor function, to children and adults living with SMA," said David L. Hallal, Chairman and Chief Executive of Scholar Rock. "We are grateful to the FDA, Cure SMA, and our colleagues at Novo Nordisk for the positive engagement at our in-person Type A meeting earlier this week. We are encouraged by the discussion and by our shared understanding of the urgency to bring this important treatment to the SMA community as rapidly as possible." Mr. Hallal continued, "In parallel, we are equally focused on establishing Scholar Rock as the global leader in myostatin biology and muscle-targeted therapeutics, and we will continue to advance key strategic programs with tight financial discipline." Business Highlights and Upcoming Milestones Apitegromab Apitegromab is an investigational fully human monoclonal antibody designed to inhibit myostatin activation by selectively binding the pro- and latent forms of myostatin in skeletal muscle. It is the first and only muscle-targeted therapeutic candidate in SMA to demonstrate statistically significant and clinically meaningful benefit in a pivotal Phase 3 clinical trial (SAPPHIRE). SMA Program  |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](srrk-20251114xex99d1g002.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Exhibit 99.1 • Completed Type A meeting with FDA. On November 12, 2025, Scholar Rock had a Type A meeting with the U.S. Food and Drug Administration (FDA). The meeting was held in person and was constructive. Catalent Indiana, LLC (part of Novo Nordisk) joined Scholar Rock at the meeting and detailed the progress it has made in implementing the remediation plan, and affirmed that it expects the facility to be ready for reinspection by the end of this year. Resubmission of the BLA and U.S. launch following approval of apitegromab for children and adults with SMA is anticipated in 2026. • Accelerated timelines with second fill-finish facility. Scholar Rock has accelerated timelines with an additional fill-finish facility for apitegromab. The facility is a commercially approved facility that is based in the U.S. and has a proven track record of successful site inspections. Tech transfer is underway, and commercial capacity has been reserved beginning in the first quarter of 2026. • European Medicines Agency (EMA) regulatory review ongoing. Scholar Rock continues to expect a decision on its apitegromab Marketing Authorisation Application (MAA) by mid-2026. • Disease awareness and education activities remain underway. U.S. customer-facing teams are in the field and continue to engage with key stakeholders on SMA disease awareness initiatives as well as on the unmet need and the importance of targeting muscle. In Europe, disease awareness and market access initiatives continue in key markets. • Initiated dosing in Phase 2 OPAL clinical trial. This trial is designed to evaluate apitegromab in infants and toddlers with SMA under two years of age who have been treated with an SMN1- targeted gene therapy or who are receiving treatment with an approved SMN2-targeted therapy. Additional Indications • Clinical development activities in second indication to initiate by YE 2025. Scholar Rock expects to initiate clinical development activities in a second neuromuscular disorder by year-end 2025. The Company plans to provide additional information on the disease and the clinical development strategy in early 2026. SRK-439 SRK-439 is a novel, investigational, subcutaneously administered myostatin inhibitor that binds to pro-and latent myostatin with high affinity and selectivity (i.e., no GDF11 or Activin A binding). Based on preclinical data, SRK-439 has the potential to potently inhibit myostatin and increase muscle mass. • FDA cleared IND in Q4 2025. Scholar Rock expects to initiate dosing of SRK-439 in healthy volunteers in the fourth quarter of 2025. Third Quarter 2025 Financial Results Scholar Rock reported a net loss of $102.2 million, including stock-based compensation of $18.3 million, for the quarter ended September 30, 2025, compared to a net loss of $64.5 million, including stock-based compensation of $9.7 million, for the quarter ended September 30, 2024. Net loss per common share was $0.90 for the quarter ended September 30, 2025 compared to $0.66 per common share for the quarter ended September 30, 2024.  |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](srrk-20251114xex99d1g004.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Exhibit 99.1 Availability of Other Information About Scholar Rock Investors and others should note that we communicate with our investors and the public using our company website www.scholarrock.com, including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on X (formerly known as Twitter) and LinkedIn. The information that we post on our website or on X (formerly known as Twitter) or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended. Forward-Looking Statements This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding Scholar Rock's future expectations, plans and prospects, including without limitation, Scholar Rock's expectations regarding its growth, strategy, progress and timing of its clinical trials for apitegromab, SRK-439 and its preclinical programs, and indication selection and development timing, including the timing of any regulatory submissions and anticipated approvals, the therapeutic potential, clinical benefits and safety of any product candidates, its ability to address the observations identified in the complete response letter, its cash runway into 2027, expectations regarding commercial launch timing in the US and in Europe, expectations regarding a new fill finish facility and the achievement of important milestones, the ability of any product candidate to perform in humans in a manner consistent with earlier nonclinical, preclinical or clinical trial data, and the potential of its product candidates and proprietary platform. The use of words such as "may," "might," "could," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "project," "intend," "future," "potential," or "continue," and other similar expressions are intended to identify such forward-looking statements. All such forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, without limitation, whether preclinical and clinical data, including the results from the Phase 3 SAPPHIRE trial, will be sufficient to support regulatory approval, that preclinical and clinical data, including the results from the Phase 2 or Phase 3 clinical trial of apitegromab, or the preclinical data for SRK-439, are not predictive of, may be inconsistent with, or more favorable than, data generated from future or ongoing clinical trials of the same product candidates; whether the FDA will accept the remediations to the Novo Nordisk Bloomington Indiana fill finish facility in response to the FDA Observations, whether Scholar Rock will be able to resubmit its BLA in a timely manner and whether the updated BLA will be sufficient to support regulatory approval, Scholar Rock's ability to manage expenses or provide the financial support, resources and expertise necessary to identify and develop product candidates on the expected timeline; information provided or decisions made by regulatory authorities; competition from third parties that are developing products for similar uses; Scholar Rock's ability to obtain, maintain and protect its intellectual property; and Scholar Rock's dependence on third parties for development and manufacture of product candidates including, without limitation, to supply any clinical trials as well as those risks more fully discussed in the section entitled "Risk Factors" in Scholar Rock's Quarterly Report on Form 10- Q for the quarter ended September 30, 2025, as well as discussions of potential risks, uncertainties, and other important factors in Scholar Rock's subsequent filings with the Securities and Exchange Commission. Any forward-looking statements represent Scholar Rock's views only as of today and should not be relied upon as representing its views as of any subsequent date. All information in this  |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](srrk-20251114xex99d1g005.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Exhibit 99.1 press release is as of the date of the release, and Scholar Rock undertakes no duty to update this information unless required by law. Investor Contact Laura Ekas, Ph.D. Scholar Rock 2025 2024 2025 2024 Operating expenses Research and development $50,486 $48,719 $161,565 $134,185 General and administrative 53,064 16,061 131,184 48,512 Total operating expenses 103,550 64,780 292,749 182,697 Loss from operations (103550) (64780) (292749) (182697) Other income (expense), net 1,330 301 5,775 2,857 Net loss $(102220) $(64479) $(286974) $(179840) $(0.90) $(0.66) $(2.54) $(1.86) 113,729,850 97,050,637 112,763,974 96,587,149 Three Months Ended September 30, Net loss per share, basic and diluted Nine Months Ended September 30, Scholar Rock Holding Corporation Condensed Consolidated Statements of Operations (unaudited) (in thousands, except share and per share data) Weighted average common shares outstanding, basic and diluted September 30, 2025 December 31, 2024 Cash, cash equivalents and marketable securities $369,630 $437,278 Other current assets 21,081 13,887 Total current assets 390,711 451,165 Other assets 21,007 23,757 $411,718 $474,922 Current liabilities $61,972 $46,936 Long-term liabilities 104,751 59,352 Total liabilities 166,723 106,288 Total stockholders' equity 244,995 368,634 $411,718 $474,922 Assets Scholar Rock Holding Corporation Condensed Consolidated Balance Sheets (unaudited) Total liabilities and stockholders' equity Total assets Liabilities and Stockholders' Equity (in thousands) |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](srrk-20251114xex99d1g006.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Exhibit 99.1 ir@scholarrock.com 917 -439 -0374 Media Contact Molly MacLeod media@scholarrock.com 802 -579 -5995 |

---

## Exhibit 99.2

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](srrk-20251114xex99d2g001.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;November 14, 2025© 2025 Scholar Rock, Inc. All rights reserved. Q3 2025 Earnings Call 1 Exhibit 99.2 |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](srrk-20251114xex99d2g002.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Q3 EARNINGS CALL© 2025 Scholar Rock, Inc. All rights reserved. 2 TOPIC SPEAKER BUSINESS UPDATE David L. Hallal Chairman & Chief Executive Officer R&D PROGRESS Akshay Vaishnaw, M.D., Ph.D. President of R&D COMMERCIAL UPDATE Keith Woods Chief Operating Officer COMPANY FINANCIALS Vikas Sinha Chief Financial Officer Q&A SESSION  |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](srrk-20251114xex99d2g003.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Forward-looking statements© 2025 Scholar Rock, Inc. All rights reserved. 3© 2025 Scholar Rock, Inc. All rights reserved. This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding Scholar Rock's future expectations, plans and prospects, including without limitation, Scholar Rock's expectations regarding its growth, strategy, progress and timing of its clinical trials for apitegromab, SRK-439 and its preclinical programs, and indication selection and development timing, including the timing of any regulatory submissions and anticipated approvals, the therapeutic potential, clinical benefits and safety of any product candidates, its ability to address the observations identified in the complete response letter, its cash runway into 2027, expectations regarding commercial launch timing in the US and in Europe, expectations regarding a new fill finish facility and the achievement of important milestones, the ability of any product candidate to perform in humans in a manner consistent with earlier nonclinical, preclinical or clinical trial data, and the potential of its product candidates and proprietary platform. The use of words such as "may," "might," "could," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "project," "intend," "future," "potential," or "continue," and other similar expressions are intended to identify such forward-looking statements. All such forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, Scholar Rock's ability to manage expenses or provide the financial support, resources and expertise necessary to identify and develop product candidates on the expected timeline; information provided or decisions made by regulatory authorities; competition from third parties that are developing products for similar uses; Scholar Rock's ability to obtain, maintain and protect its intellectual property; and Scholar Rock's dependence on third parties for development and manufacture of product candidates including, without limitation, to supply any clinical trials as well as those risks more fully discussed in the section entitled "Risk Factors" in Scholar Rock's Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, as well as discussions of potential risks, uncertainties, and other important factors in Scholar Rock's subsequent filings with the Securities and Exchange Commission. Any forward-looking statements represent Scholar Rock's views only as of today and should not be relied upon as representing its views as of any subsequent date. All information in this presentation is as of the date of the presentation, and Scholar Rock undertakes no duty to update this information unless required by law. Apitegromab and SRK-439 have not been approved for any use by the FDA or any other regulatory agency and the safety and efficacy of apitegromab and SRK-439 have not been established. |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](srrk-20251114xex99d2g004.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;BUSINESS UPDATE© 2025 Scholar Rock, Inc. All rights reserved. 4 David L. Hallal Chairman and Chief Executive Officer  |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](srrk-20251114xex99d2g005.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;R&D PROGRESS© 2025 Scholar Rock, Inc. All rights reserved. 5 Akshay Vaishnaw, M.D., Ph.D. President of R&D |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](srrk-20251114xex99d2g006.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;COMMERCIAL UPDATE© 2025 Scholar Rock, Inc. All rights reserved. 6 Keith Woods Chief Operating Officer  |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](srrk-20251114xex99d2g007.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;COMPANY FINANCIALS© 2025 Scholar Rock, Inc. All rights reserved. 7 Vikas Sinha Chief Financial Officer |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](srrk-20251114xex99d2g008.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CLOSING REMARKS© 2025 Scholar Rock, Inc. All rights reserved. 8 David L. Hallal Chairman and Chief Executive Officer  |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](srrk-20251114xex99d2g009.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Q&A© 2025 Scholar Rock, Inc. All rights reserved. 9 |

---